NVP-QBE170: An inhaled blocker of the epithelial sodium channel with a reduced potential to induce hyperkalaemia

British Journal of Pharmacology

Volumn 172, Issue 11, 2015, Pages 2814-2826

  Coote, K J ^a   Paisley, D ^a   Czarnecki, S ^a   Tweed, M ^a   Watson, H ^a   Young, A ^a   Sugar, R ^a   Vyas, M ^a   Smith, N J ^a   Baettig, U ^a   Groot Kormelink, P J ^a   Gosling, M ^a   Lock, R ^a   Ethell, B ^a   Williams, G ^a   Schumacher, A ^b   Harris, J ^b   Abraham, W M ^c   Sabater, J ^c   Poll, C T ^d   Faller, T ^a   Collingwood, S P ^a   Danahay, H ^a,e   more..

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b Genomic Inst of the Novartis Found   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d London BioScience Innovation Center   (United Kingdom)

^e UNIVERSITY OF SUSSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; EPITHELIAL SODIUM CHANNEL BLOCKING AGENT; NVP QBE 170; UNCLASSIFIED DRUG; DIPHENYL ETHER DERIVATIVE; N-(3,5-DIAMINO-6-CHLOROPYRAZINE-2-CARBONYL)-N'-4-(4-(2,3-DIHYDROXYPROPOXY)PHENYL)BUTYLGUANIDINE; NVP-QBE170; PIPERIDINE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG POTENCY; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; GUINEA PIG; HUMAN; HUMAN CELL; HYPERKALEMIA; IC50; IN VIVO STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; SHEEP; TREATMENT DURATION; ANALOGS AND DERIVATIVES; ANIMAL; CHEMICALLY INDUCED; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; EPITHELIUM CELL; IN VITRO STUDY; INHALATIONAL DRUG ADMINISTRATION; MUCOCILIARY CLEARANCE; RESPIRATORY MUCOSA;

ADMINISTRATION, INHALATION; AMILORIDE; ANIMALS; EPITHELIAL CELLS; EPITHELIAL SODIUM CHANNEL BLOCKERS; GUINEA PIGS; HYPERKALEMIA; IN VITRO TECHNIQUES; MUCOCILIARY CLEARANCE; PHENYL ETHERS; PIPERIDINES; RATS; RESPIRATORY MUCOSA; SHEEP;

EID: 84929175850     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13075     Document Type: Article

References (45)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. App EM, King M, Helfesrieder R, Köhler D, Matthys H, (1990). Acute and long-term amiloride inhalation in cystic fibrosis lung disease. A rational approach to cystic fibrosis therapy. Am Rev Respir Dis 141: 605-612.
4. Boucher RC, (2007). Evidence for airway surface dehydration as the initiating event in CF airway disease. J Intern Med 261: 5-16.
5. Boucher RC, Cotton CU, Gatzy JT, Knowles MR, Yankaskas JR, (1988). Evidence for reduced Cl- and increased Na+ permeability in cystic fibrosis human primary cell cultures. J Physiol 405: 77-103.
6. Bowler IM, Kelman B, Worthington D, Littlewood JM, Watson A, Conway SP, et al. (1995). Nebulised amiloride in respiratory exacerbations of cystic fibrosis: a randomised controlled trial. Arch Dis Child 73: 427-430.
7. Canessa CM, Horisberger JD, Rossier BC, (1993). Epithelial sodium channel related to proteins involved in neurodegeneration. Nature 361: 467-470.
8. Chang SS, Grunder S, Hanukoglu A, Rösler A, Mathew PM, Hanukoglu I, et al. (1996). Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 12: 248-253.
9. Chen JH, Stoltz DA, Karp PH, Ernst SE, Pezzulo AA, Moninger TO, et al. (2010). Loss of anion transport without increased sodium absorption characterizes newborn porcine cystic fibrosis airway epithelia. Cell 143: 911-923.
10. Coote K, Atherton-Watson HC, Sugar R, Young A, MacKenzie-Beevor A, Gosling M, et al. (2009). Camostat attenuates airway epithelial sodium channel function in vivo through the inhibition of a channel-activating protease. J Pharmacol Exp Ther 329: 764-774.
11. Coote KJ, Atherton H, Young A, Sugar R, Burrows R, Smith NJ, et al. (2008). The guinea-pig tracheal potential difference as an in vivo model for the study of epithelial sodium channel function in the airways. Br J Pharmacol 155: 1025-1033.
12. Donaldson S, Smith R, Doran J, DiMassimo B, Zeman K, Bennett B, et al. (2005). Safety, pharmacokinetics and effects on mucus clearance following administration of 552-02 to normal healthy volunteers. Pediatr Pulmonol 40: 218, Abstract.
13. Donaldson SH, Bennett WD, Zeman KL, Knowles MR, Tarran R, Boucher RC, (2006). Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 354 (3): 241-250.
14. Elkins MR, Robinson M, Rose BR, Harbour C, Moriarty CP, Marks GB, et al. (2006). A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 354: 229-240.
15. Frelin C, Barbry P, Vigne P, Chassande O, Cragoe EJ Jr, Lazdunski M, (1988). Amiloride and its analogs as tools to inhibit Na+ transport via the Na+ channel, the Na+/H + antiport and the Na+/Ca2+ exchanger. Biochimie 70: 1285-1290.
16. Graham A, Hasani A, Alton EW, Martin GP, Marriott C, Hodson ME, et al. (1993). No added benefit from nebulized amiloride in patients with cystic fibrosis. Eur Respir J 6: 1243-1248.
17. Hirsh A, (2002). Altering airway surface liquid volume: inhalation therapy with amiloride and hyperosmotic agents. Adv Drug Deliv Rev 54: 1445-1462.
18. Hirsh AJ, Sabater JR, Zamurs A, Smith RT, Paradiso AM, Hopkins S, et al. (2004). Evaluation of second generation amiloride analogs as therapy for cystic fibrosis lung disease. J Pharmacol Exp Ther 311: 929-938.
19. Hirsh AJ, Zhang J, Zamurs A, Fleegle J, Thelin WR, Caldwell RA, et al. (2008). Pharmacological properties of N-(3,5-diamino-6-chloropyrazine-2-carbonyl)-N'-4-[4-(2,3-dihydroxypropoxy)phenyl]butyl-guanidine methanesulfonate (552-02), a novel epithelial sodium channel blocker with potential clinical efficacy for cystic fibrosis lung disease. J Pharmacol Exp Ther 325: 77-88.
20. Hofmann T, Senier I, Bittner P, Hüls G, Schwandt HJ, Lindemann H, (1997). Aerosolized amiloride: dose effect on nasal bioelectric properties, pharmacokinetics, and effect on sputum expectoration in patients with cystic fibrosis. J Aerosol Med 10: 147-158.
21. Itani OA, Chen JH, Karp PH, Ernst S, Keshavjee S, Parekh K, et al. (2011). Human cystic fibrosis airway epithelia have reduced Cl- conductance but not increased Na+ conductance. Proc Natl Acad Sci U S A 108: 10260-10265.
22. Jespersen T, Grunnet M, Angelo K, Klaerke DA, Olesen SP, (2002). Dual-function vector for protein expression in both mammalian cells and Xenopus laevis oocytes. Biotechniques 32: 536-538, 540.
23. Kellenberger S, Schild L, (2002). Epithelial sodium channel/degenerin family of ion channels: a variety of functions for a shared structure. Physiol Rev 82: 735-767.
24. Kerem E, Bistritzer T, Hanukoglu A, Hofmann T, Zhou Z, Bennett W, et al. (1999). Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 341: 156-162.
25. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
26. Knowles M, Gatzy J, Boucher R, (1981). Increased bioelectric potential difference across respiratory epithelia in cystic fibrosis. N Engl J Med 305: 1489-1495.
27. Knowles MR, Church NL, Waltner WE, Yankaskas JR, Gilligan P, King M, et al. (1990). A pilot study of aerosolized amiloride for the treatment of lung disease in cystic fibrosis. N Engl J Med 322: 1189-1194.
28. Köhler D, App E, Schmitz-Schumann M, Würtemberger G, Matthys H, (1986). Inhalation of amiloride improves the mucociliary and the cough clearance in patients with cystic fibroses. Eur J Respir Dis Suppl 146: 319-326.
29. Kusama M, Toshimoto K, Maeda K, Hirai T, Imai S, Chiba K, et al. (2010). In Silico Classification of major clearance pathways of drugs with their physiochemical parameters. Drug Metab Dispos 38: 1362-1370.
30. Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC, (2004). Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice. Nat Med 10: 487-493.
31. Matsui H, Grubb BR, Tarran R, Randell SH, Gatzy JT, Davis CW, et al. (1998). Evidence for periciliary liquid layer depletion, not abnormal ion composition, in the pathogenesis of cystic fibrosis airways disease. Cell 95: 1005-1015.
32. McGrath JC, Drummond GB, McLachlan EM, Kilkenny C, Wainwright CL, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
33. Noone PG, Regnis JA, Liu X, Brouwer KL, Robinson M, Edwards L, et al. (1997). Airway deposition and clearance and systemic pharmacokinetics of amiloride following aerosolization with an ultrasonic nebulizer to normal airways. Chest 112: 1283-1290.
34. O'Riordan TG, Donn KH, Hodsman P, Ansede JH, Newcomb T, Lewis SA, et al. (2014). Acute hyperkalemia associated with inhalation of a potent ENaC antagonist: phase 1 trial of GS-9411. J Aerosol Med Pulm Drug Deliv 27: 200-208.
35. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl Acids Res 42 (Database Issue): D1098-D1106.
36. Perazella MA, (2000). Drug-induced hyperkalemia: old culprits and new offenders. Am J Med 109: 307-314.
37. Pons G, Marchand MC, d'Athis P, Sauvage E, Foucard C, Chaumet-Riffaur P, et al. (2000). Amiloride-AFLM Collaborative Study Group: French multicenter randomized double-blind placebo-controlled trial on nebulized amiloride in cystic fibrosis patients. Pediatr Pulmonol 30: 25-31.
38. Quinton PM, (1989). Defective epithelial ion transport in cystic fibrosis. Clin Chem 35: 726-730.
39. Riordan JR, Rommens JM, Kerem B, Alon N, Rozmahel R, Grzelczak Z, et al. (1989). Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. Science 245: 1066-1073.
40. Schild L, Schneeberger E, Gautschi I, Firsov D, (1997). Identification of amino acid residues in the alpha, beta, and gamma subunits of the epithelial sodium channel (ENaC) involved in amiloride block and ion permeation. J Gen Physiol 109: 15-26.
41. Sheppard DN, Carson MR, Ostedgaard LS, Denning GM, Welsh MJ, (1994). Expression of cystic fibrosis transmembrane conductance regulator in a model epithelium. Am J Physiol 266: L405-L413.
42. Staruschenko A, Booth RE, Pochynyuk O, Stockand JD, Tong Q, (2006). Functional reconstitution of the human epithelial Na+ channel in a mammalian expression system. Methods Mol Biol 337: 3-13.
43. Strautnieks SS, Thompson RJ, Gardiner RM, Chung E, (1996). A novel splice-site mutation in the gamma subunit of the epithelial sodium channel gene in three pseudohypoaldosteronism type 1 families. Nat Genet 13: 248-250.
44. Varma MVS, Feng BR, Obach RS, Troutman MD, Chupka J, Miller HR, et al. (2009). Physicochemical determinants of human renal clearance. J Med Chem 52: 4844-4852.
45. Zhou Z, Treis D, Schubert SC, Harm M, Schatterny J, Hirtz S, et al. (2008). Preventive but not late amiloride therapy reduces morbidity and mortality of lung disease in betaENaC-overexpressing mice. Am J Respir Crit Care Med 178: 1245-1256.